Cargando…
Correlation of Cytokine Release Syndrome With Prognosis After Chimeric Antigen Receptor T Cell Therapy: Analysis of 54 Patients With Relapsed or Refractory Multiple Myeloma
Although chimeric antigen receptor T (CAR-T) cell therapy has proven to be effective in treating relapsed or refractory multiple myeloma (R/R MM), the severity of cytokine release syndrome (CRS) can affect patient survival and the risk factors for CRS remain an intractable issue. We enrolled 54 pati...
Autores principales: | Wang, Xue, Zhao, Lina, Wang, Jing, Yao, Yue, Wang, Jiaojiao, Ji, Shengwei, Hua, Tian, Wang, Shiyuan, Cheng, Hai, Shi, Ming, Li, Zhenyu, Zeng, Lingyu, Zheng, Junnian, Xu, Kailin, Cao, Jiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092941/ https://www.ncbi.nlm.nih.gov/pubmed/35572513 http://dx.doi.org/10.3389/fimmu.2022.814548 |
Ejemplares similares
-
Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma
por: Li, Hujun, et al.
Publicado: (2022) -
Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia
por: Hong, Fei, et al.
Publicado: (2021) -
Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment
por: Yan, Zhiling, et al.
Publicado: (2021) -
Prognostic value of prelymphodepletion absolute lymphocyte counts in relapsed/refractory diffuse large B-cell lymphoma patients treated with chimeric antigen receptor T cells
por: Lu, Yanyan, et al.
Publicado: (2023) -
Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma
por: Zhang, Lina, et al.
Publicado: (2021)